Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amartej Merla

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Chemotherapy Research and Practice|October 26, 2012
Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic reviewAmartej Merla, Sanjay Goel
Drugs|March 1, 2014
Targeting angiogenesis in squamous non-small cell lung cancerBilal Piperdi, Amartej Merla, Roman Perez-Soler
Current Treatment Options in Oncology|August 13, 2015
Targeted Therapy in Biliary Tract CancersAmartej Merla, Kenneth G Liu, Lakshmi Rajdev
Cancer Treatment and Research|August 23, 2025
Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in CancerPrakash Kulkarni, Sravani Ramisetty, Debora Bruno, et al.
JCO Oncology Practice|January 5, 2022
Tragic Triad of Tobacco Dependence, Cancer, and COVID-19 Pandemic: An Urgent Call for Attention by Health Care Systems and ProfessionalsCary A Presant, Jonjon Macalintal, Kimlin Tam Ashing, et al.
Biomolecules|November 25, 2023
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung CancerPrakash Kulkarni, Atish Mohanty, Sravani Ramisetty, et al.
Journal of Clinical Medicine|March 11, 2023
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision MedicineMartin Sattler, Isa Mambetsariev, Jeremy Fricke, et al.
Journal of Clinical Medicine|November 26, 2022
Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care PlansLinda D Bosserman, Isa Mambetsariev, Colton Ladbury, et al.
Oncotarget|October 1, 2019
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatinDevika Rao, Atrayee Basu Mallick, Titto Augustine, et al.
Cancer Causes & Control : CCC|October 12, 2022
Increasing clinician participation in tobacco cessation by an implementation science-based tobacco cessation champion programCary A Presant, Kimlin Ashing, Sophia Yeung, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Chemotherapy Research and Practice|October 26, 2012
Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic reviewAmartej Merla, Sanjay Goel
Drugs|March 1, 2014
Targeting angiogenesis in squamous non-small cell lung cancerBilal Piperdi, Amartej Merla, Roman Perez-Soler
Current Treatment Options in Oncology|August 13, 2015
Targeted Therapy in Biliary Tract CancersAmartej Merla, Kenneth G Liu, Lakshmi Rajdev
Cancer Treatment and Research|August 23, 2025
Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in CancerPrakash Kulkarni, Sravani Ramisetty, Debora Bruno, et al.
JCO Oncology Practice|January 5, 2022
Tragic Triad of Tobacco Dependence, Cancer, and COVID-19 Pandemic: An Urgent Call for Attention by Health Care Systems and ProfessionalsCary A Presant, Jonjon Macalintal, Kimlin Tam Ashing, et al.
Biomolecules|November 25, 2023
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung CancerPrakash Kulkarni, Atish Mohanty, Sravani Ramisetty, et al.
Journal of Clinical Medicine|March 11, 2023
A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision MedicineMartin Sattler, Isa Mambetsariev, Jeremy Fricke, et al.
Journal of Clinical Medicine|November 26, 2022
Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care PlansLinda D Bosserman, Isa Mambetsariev, Colton Ladbury, et al.
Oncotarget|October 1, 2019
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatinDevika Rao, Atrayee Basu Mallick, Titto Augustine, et al.
Cancer Causes & Control : CCC|October 12, 2022
Increasing clinician participation in tobacco cessation by an implementation science-based tobacco cessation champion programCary A Presant, Kimlin Ashing, Sophia Yeung, et al.
Pageof 2